Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed death-ligand 1 (PD-L1)] became the first approved treatment for patients with metastatic MCC (mMCC), based on efficacy and safety data obse...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Angelo, S.P., Bhatia, S., Brohl, A.S., Hamid, O., Mehnert, J.M., Terheyden, P., Shih, K.C., Brownell, I., Lebbé, C., Lewis, K.D., Linette, G.P., Milella, M., Xiong, H., Guezel, G., Nghiem, P.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564559/
https://www.ncbi.nlm.nih.gov/pubmed/34715570
http://dx.doi.org/10.1016/j.esmoop.2021.100290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564559/
https://www.ncbi.nlm.nih.gov/pubmed/34715570
http://dx.doi.org/10.1016/j.esmoop.2021.100290

Ejemplares similares